Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma

NCT05143112 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Non-hodgkin Lymphoma,B Cell

Interventions

BIOLOGICAL: Allogeneic CD19 CR-T cell

Sponsor

Shenzhen University General Hospital